Loading…
Shandra Eisenga Human Cell and Tissue Product Safety Act
Legislative Progress
Introduced
February 1, 2024
Latest Action
December 17, 2024
Primary Sponsor
John R. MoolenaarRepublican(MI)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
91pct
320d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2024 · fourth_quarter · Science/Technology
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act
Client expense: $30,000 · Firm income: Not reported
Received in the Senate.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.
Considered under suspension of the rules. (consideration: CR H7167-7170)
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 632.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.
Congress.gov source codes: 5000, H12200
Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
H.R.7188/S.3733 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Science/Technology
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act HR 4758 / S 2372, Accelerating Kids Access to Care Act
Client expense: $30,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
Site neutral payment Shandra Eisenga Human Cell and Tissue Product Safety Act (S. 3733/H.R. 7188) H.R. 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Science/Technology
HR 7188, Shandra Eisenga Human Cell and Tissue Products Safety Act House FY25 Labor-HHS appropriations bill House FY25 FSGG appropriations bill Senate FY25 FSGG appropriations bill
Client expense: $30,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Site neutral payment Shandra Eisenga Human Cell and Tissue Product Safety Act (S. 3733/H.R. 7188)
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Issues related to Human Cellular Tissue Products (HCTP)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Site neutral payment Shandra Eisenga Human Cell and Tissue Product Safety Act (S. 3733/H.R. 7188)
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Issues related to HCT/P legislation (e.g. HR 7188/S. 3733)
Client expense: Not reported · Firm income: Not reported
Committee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.
Subcommittee Consideration and Mark-up Session Held
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| February 1, 2024 |